Adcendo raises $135m for cancer ADCs, and other financings
Adcendo raises $135m for cancer ADCs, plus financings for Enveda, Cradle Bio, ATB Therapeutics, and 35Pharma
Newsletters and Deep Dive digital magazine
Adcendo raises $135m for cancer ADCs, plus financings for Enveda, Cradle Bio, ATB Therapeutics, and 35Pharma
Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China
Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours
In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline
Editor's Picks
Newsletters and Deep Dive
digital magazine